Facebook Linkedin RSS Twitter Youtube
Home 2024

Inborn genetic diseases

Gee WIZ: Novartis’ “Glue Degrader” Drug Candidate for Sickle Cell Shows Promise in Animal Studies
GEN Edge

Gee WIZ: Novartis’ “Glue Degrader” Drug Candidate for Sickle Cell Shows Promise in Animal Studies

Standardized Cell and Gene Therapy Hub A Call to Action
Bioprocessing

Standardized Cell and Gene Therapy Hub A Call to Action

CRISPR 2.0: Kinder, Gentler, More Powerful Gene Editing
Genome Editing

CRISPR 2.0: Kinder, Gentler, More Powerful Gene Editing

ASGCT 2024: David Liu Touts Rapid Evolution of Gene-Sized Programmable Editing Technologies
Genome Editing

ASGCT 2024: David Liu Touts Rapid Evolution of Gene-Sized Programmable Editing Technologies

2025 Cell & Gene Therapy Reimbursement Outlook
Bioprocessing

2025 Cell & Gene Therapy Reimbursement Outlook

CRISPR Concerns Won’t Spoil Its Promise—If We Use the Right Tools
GEN Edge

CRISPR Concerns Won’t Spoil Its Promise—If We Use the Right Tools

Rare Disease Day: Moderna Gets Back to Its Roots
Drug Discovery

Rare Disease Day: Moderna Gets Back to Its Roots

On the Charge: MaxCyte Celebrates Role in Sickle Cell Therapy Breakthrough
GEN Edge

On the Charge: MaxCyte Celebrates Role in Sickle Cell Therapy Breakthrough

Sickle Cell Salvation: The Victoria Gray Interview
Genome Editing

Sickle Cell Salvation: The Victoria Gray Interview

Ultragenyx’s Gene Therapy Ameliorates Pediatric Neurodegenerative Disorder
Drug Discovery

Ultragenyx’s Gene Therapy Ameliorates Pediatric Neurodegenerative Disorder

123...14Page 1 of 14
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.